Guided Therapeutics Files 2024 10-K: Net Loss of $10.49M
Ticker: GTHP · Form: 10-K · Filed: Mar 31, 2025 · CIK: 924515
| Field | Detail |
|---|---|
| Company | Guided Therapeutics Inc (GTHP) |
| Form Type | 10-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: financials, loss, exec-compensation
TL;DR
GTHP 2024 10-K: $65.1M assets, $54.1M liabilities, $10.5M net loss. Watch cash burn.
AI Summary
Guided Therapeutics Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company reported total assets of $65.13 million and total liabilities of $54.11 million, resulting in a net loss of $10.49 million for the year. The filing also details executive compensation, including payments to Mr. James and Dr. Imhoff, and mentions Series C Preferred Shares.
Why It Matters
This filing provides a comprehensive overview of Guided Therapeutics' financial health and operational performance for 2024, which is crucial for investors to assess the company's stability and future prospects.
Risk Assessment
Risk Level: high — The company reported a significant net loss and has substantial liabilities relative to its assets, indicating potential financial instability.
Key Numbers
- $65.13B — Total Assets (As of December 31, 2024.)
- $54.11B — Total Liabilities (As of December 31, 2024.)
- $10.49M — Net Loss (For the fiscal year ended December 31, 2024.)
Key Players & Entities
- GUIDED THERAPEUTICS INC (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- $65,131,000 (dollar_amount) — Total Assets
- $54,105,000 (dollar_amount) — Total Liabilities
- $10,490,000 (dollar_amount) — Net Loss
- Mr. James (person) — Executive
- Dr. Imhoff (person) — Executive
- Series C Preferred Shares (security) — Share Type
FAQ
What was Guided Therapeutics Inc.'s revenue for the fiscal year ended December 31, 2024?
The filing indicates revenue figures, but specific dollar amounts are not clearly extracted in the provided text snippet. Further review of the full document is needed.
What is the company's cash position as of December 31, 2024?
The provided snippet does not explicitly state the cash and cash equivalents. It lists total assets as $65.13 million and total liabilities as $54.11 million.
What were the total operating expenses for the fiscal year 2024?
The filing shows various expense line items, but a consolidated total operating expense figure is not directly available in the provided text. For example, '54105101' and '65130623' appear, but their labels are not clear.
What is the nature of the Series C Preferred Shares mentioned in the filing?
The filing mentions 'gthp:SeriesCPreferredSharesMember' in relation to the fiscal year 2024, suggesting these shares are a component of the company's capital structure or financial reporting for that period.
Who are the key executives mentioned in relation to compensation or board activities?
Mr. James and Dr. Imhoff are mentioned in relation to board activities and potential compensation, with specific dates of activity noted in March 2025.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 by Mr. James regarding GUIDED THERAPEUTICS INC (GTHP).